Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and preparing method for preparation

A technology of mesenchymal stem cells and cytokines, applied in the field of mesenchymal stem cells and their cytokine preparations and preparations, can solve the problems of low drug absorption rate, large trauma, limited curative effect, etc., achieve great application value, and prevent side effects and damage , the effect of treating premature ovarian failure

Pending Publication Date: 2015-10-07
CHENGDU QINGKE BIOTECH
View PDF5 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] An object of the present invention is to provide a kind of mesenchymal stem cells and cytokine preparations with therapeutic effect on premature ovarian failure and perimenopausal syndrome, which solves the current problem The problems of low absorption rate, limited curative effect and large trauma caused by the treatment of premature ovarian failure and perimenopausal syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and preparing method for preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] In this example, the mesenchymal stem cells and their cytokine preparations having the therapeutic effect on premature ovarian failure and perimenopausal syndrome are prepared by mixing placental mesenchymal stem cells and their cytokines with hyaluronate in a ratio of 1:1 suspension; in this suspension, the final concentration of placental mesenchymal stem cells was 1×10 7 pieces / ml, the final concentration of hyaluronate is 0.01% by mass fraction, and the molecular weight of hyaluronate is 1 million Daltons.

[0033] Wherein, the above-mentioned placental mesenchymal stem cells are prepared by the following method:

[0034] Take refrigerated placentas from volunteers, who are healthy and qualified, and 24 to 72 hours postpartum. Use hemostatic forceps to peel off the amniotic membrane tissue on the placenta, and then use fine scissors to cut a sufficient amount of placental chorionic tissue from the placenta. After cleaning, use tissue forceps Remove the vascular tis...

Embodiment 2

[0038] The mesenchymal stem cells and their cytokine preparations, which have the therapeutic effect on premature ovarian failure and perimenopausal syndrome, are prepared by mixing umbilical cord mesenchymal stem cells and their cytokines with hyaluronate at a ratio of 1:3 suspension; in this suspension, the final concentration of umbilical cord mesenchymal stem cells was 5×10 7 pieces / ml, the final concentration of hyaluronate is 0.02% by mass fraction, and the molecular weight of hyaluronate is 1.5 million Daltons.

[0039] Wherein, the above-mentioned umbilical cord mesenchymal stem cells are prepared by the following method:

[0040] Take voluntary, healthy and qualified umbilical cords of refrigerated neonates 24-72 hours postpartum, soak and disinfect them, cut them into small pieces with a length of 3-4cm, and remove the blood vessels (one vein and two arteries) in each section of umbilical cord with hemostatic forceps , separate the umbilical cord tissue from the ski...

Embodiment 3

[0050] Treatment of perimenopausal syndrome with the mesenchymal stem cell cytokine preparation prepared in Example 1

[0051] Patient: Li **, female, 49 years old. Symptoms: vaginal dryness, relaxation, decreased libido, poor sleep, menopause for 1 year, and suffering from "fungal vaginitis" with recurrent attacks.

[0052] Patient Characteristics: 1. Middle-aged women, G3P2 (cis 2); 2. Stop menstruation for 9 months; 3. Want to improve symptoms such as vaginal dryness, relaxation, and poor libido.

[0053] Gynecological examination status: .Vulva dryness, laxity, pigmentation of labia minora on both sides; vaginal relaxation of about 3 fingers, poor vaginal wrapping and suction; posterior uterus, normal size, movement, hard tenderness, bilateral appendages without obvious abnormalities.

[0054] Auxiliary inspection: Leucorrhea test: Cleanliness Ⅱ; HBsAg: (—), HBeAg: (—), HIV: (—), HCV: (—), TP: (—), B-ultrasound, ECG examination was normal.

[0055] diagnosis : 1, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

Description

technical field [0001] The invention relates to the technical field of biomedicine, and relates to the transformation and application of mesenchymal stem cells in the field of regenerative medicine, and in particular to mesenchymal stem cells with therapeutic effects on premature ovarian failure and perimenopausal syndrome, a cytokine preparation and a preparation method thereof. Background technique [0002] Premature ovarian failure refers to women who have established regular menstruation. Before the age of 40, persistent amenorrhea and sexual organ atrophy occur due to ovarian function decline. There is often an increase in gonadotropin levels and a decrease in estrogen. The incidence rate is about 1%~3%, and the incidence rate within 30 years old is about 0.1%. The clinical manifestations are accompanied by different degrees of hot flashes, hyperhidrosis, insomnia, irritability, palpitations, fatigue, emotional tension, vaginal dryness, low sexual function, infertility,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61K38/19A61K47/36A61K9/10A61P15/08A61P15/12A61K31/728
Inventor 陈静娴张宗容海泉胡忠国赵令卉王翔赵峻
Owner CHENGDU QINGKE BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com